Friday, November 22, 2013 9:41:49 AM
Life Stem Genetics, Inc. (LIFS) announced today a strategic collaborative agreement with American CryoStem Corporation, (CRYO). CRYO is a leading developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries.
Adipose tissue is an anatomical term for loose connective tissue (fat) composed of adipocytes (cells). It is used in LIFS stem cell procedures and currently is extracted via liposuction each time a patient has a treatment. This collaboration will give our physician’s network the ability to store a patient’s adipose tissue for future regenerative medicine applications after only one extraction process. In the absence of future liposuction procedures, the patient’s recovery time is lessened and additional procedure costs are reduced.
This collaboration will provide the Company’s physicians and medical clinics access to a FDA registered laboratory and the science of tissue collection, processing and long term storage of their patient’s adipose tissue sample collected at the point of care.
American CryoStem’s ATGRAFT™ tissue samples are processed and prepared upon arrival at their FDA registered laboratory based in Mt. Laurel, N.J., tested for adipocyte and cellular viability, and stored free of charge for six months. Long term storage fees will be billed directly to the patient by American CryoStem with revenue shared with LIFS. Stored patient samples retrieved by LIFS physicians will be shipped, ready for use without any additional processing.
Life Stem Genetics Chief Medical Stem Cell Specialist, James Vanden Bosch, BHA, commented, “This relationship secured with American CryoStem by Life Stem Genetics advances our physician’s treatment protocols from traditionally collecting and processing patients adipose tissue in the same day to establishing a treatment program not dictated by a single liposuction procedure.” Mr. Vanden Bosch further commented, “Patients can now visit a clinic and have future treatments with the same high quality adipose tissue.” he adds.
The Company expects to begin internal validation of the ATGRAFT™ service in the coming weeks prior to a full roll-out of this new offering. Additional updates about Life Stem Genetics and American CryoStem will be announced as this synergistic relationship continues to develop.
About Life Stem Genetics
Life Stem Genetics ("LSG") is a progressive healthcare company focused on Adult Stem Cell (ASC) healing therapies. For decades, stem cells have been utilized in the successful treatment of a variety of ailments. Today, advanced ASC therapies are being offered to patients as an efficient and painless alternative treatment for a wide range of ailments including, but not limited to, orthopedic injuries, neurological disorders such as Parkinson's and Alzheimer's, cancer, arthritis, diabetes, multiple sclerosis, as well as age management. Adult Stem Cell therapies and LSG's proprietary techniques are experiencing some of the best results in the industry in helping to repair or reprogram damaged or diseased tissues and organs. Life Stem's ASC specialist has performed thousands of stem cell treatments including some of the top names in PGA golf, NFL football, NBA basketball, and Major League Baseball. LSG will offer its proprietary treatments through a series of affiliate doctors and medical clinics with 60 affiliated clinics thus far. LSG's mission is to develop a comprehensive approach to the treatment and maintenance of diseases while breaking free from the medical insurance maze by tapping into an affordable private-pay sector.
News Link:
http://finance.yahoo.com/news/life-stem-genetics-announces-collaborative-133000913.html
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM